D B Hunninghake

Summary

Affiliation: University of Minnesota
Country: USA

Publications

  1. ncbi Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia
    Donald B Hunninghake
    Heart Disease Prevention Clinic, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Coron Artery Dis 15:115-23. 2004
  2. ncbi A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin
    Donald B Hunninghake
    The Heart Disease Prevention Clinic, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Clin Cardiol 26:112-8. 2003
  3. ncbi Postdischarge lipid management of coronary artery disease patients according to the new National Cholesterol Education Program guidelines
    D B Hunninghake
    University of Minnesota School of Medicine, 401 East River Parkway, Minneapolis, MN 55455, USA
    Am J Cardiol 88:37K-41K. 2001
  4. ncbi Lessons from the post coronary artery bypass graft study in evaluating and controlling technical variability in angiographic trials. Post CABG Investigators
    C W White
    Cardiovascular Division, University of Minnesota, Minneapolis 55455, USA
    Am J Cardiol 87:40-3. 2001
  5. ncbi Peripheral arterial disease detection, awareness, and treatment in primary care
    A T Hirsch
    Vascular Medicine Program, Minnesota Vascular Diseases Center, Mayo Mail Code 508, University of Minnesota Medical School, 420 Delaware St, SE, Minneapolis, MN 55455, USA
    JAMA 286:1317-24. 2001
  6. ncbi The Minnesota Regional Peripheral Arterial Disease Screening Program: toward a definition of community standards of care
    A T Hirsch
    Vascular Medicine Program, Minnesota Vascular Diseases Center, University of Minnesota Medical School, Minneapolis 55455, USA
    Vasc Med 6:87-96. 2001
  7. ncbi Effect of an aggressive lipid-lowering strategy on progression of atherosclerosis in the left main coronary artery from patients in the post coronary artery bypass graft trial
    C W White
    University of Minnesota, Minneapolis, Minnesota, USA
    Circulation 104:2660-5. 2001
  8. ncbi A summary of the findings from the Post-CABG trial
    B J Hoogwerf
    Cleveland Clinic Foundation, University of Minnesota, Cleveland, USA
    Minerva Cardioangiol 50:291-9. 2002
  9. ncbi Safety of rosuvastatin
    James Shepherd
    Department of Vascular Biochemistry, University of Glasgow, Glasgow, Scotland
    Am J Cardiol 94:882-8. 2004
  10. ncbi Plasma homocysteine levels in living kidney donors before and after uninephrectomy
    Michael Y Tsai
    Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis, 55455 0392, USA
    J Lab Clin Med 143:340-3. 2004

Detail Information

Publications24

  1. ncbi Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia
    Donald B Hunninghake
    Heart Disease Prevention Clinic, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Coron Artery Dis 15:115-23. 2004
    ..We examined the effects of rosuvastatin treatment on triglyceride levels and lipid measures in a parallel-group multicenter trial (4522IL/0035) in patients with hypertriglyceridemia (Fredrickson Type IIb or IV)...
  2. ncbi A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin
    Donald B Hunninghake
    The Heart Disease Prevention Clinic, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Clin Cardiol 26:112-8. 2003
    ..Combination therapy for dyslipidemia holds promise as effective treatment for patients with multiple lipid disorders, especially those at high risk...
  3. ncbi Postdischarge lipid management of coronary artery disease patients according to the new National Cholesterol Education Program guidelines
    D B Hunninghake
    University of Minnesota School of Medicine, 401 East River Parkway, Minneapolis, MN 55455, USA
    Am J Cardiol 88:37K-41K. 2001
    ..The challenge for the specialist is to establish a predischarge plan that includes maximal dosing to achieve aggressive target goals and to work with the patient's primary care provider to maintain these goals long-term...
  4. ncbi Lessons from the post coronary artery bypass graft study in evaluating and controlling technical variability in angiographic trials. Post CABG Investigators
    C W White
    Cardiovascular Division, University of Minnesota, Minneapolis 55455, USA
    Am J Cardiol 87:40-3. 2001
    ..4%. These data from the Post CABG trial reveal that technical variability is small and has negligible impact on the conclusions of the study...
  5. ncbi Peripheral arterial disease detection, awareness, and treatment in primary care
    A T Hirsch
    Vascular Medicine Program, Minnesota Vascular Diseases Center, Mayo Mail Code 508, University of Minnesota Medical School, 420 Delaware St, SE, Minneapolis, MN 55455, USA
    JAMA 286:1317-24. 2001
    ..Peripheral arterial disease (PAD) is a manifestation of systemic atherosclerosis that is common and is associated with an increased risk of death and ischemic events, yet may be underdiagnosed in primary care practice...
  6. ncbi The Minnesota Regional Peripheral Arterial Disease Screening Program: toward a definition of community standards of care
    A T Hirsch
    Vascular Medicine Program, Minnesota Vascular Diseases Center, University of Minnesota Medical School, Minneapolis 55455, USA
    Vasc Med 6:87-96. 2001
    ..These data can assist in the future development of PAD awareness, education, and treatment programs...
  7. ncbi Effect of an aggressive lipid-lowering strategy on progression of atherosclerosis in the left main coronary artery from patients in the post coronary artery bypass graft trial
    C W White
    University of Minnesota, Minneapolis, Minnesota, USA
    Circulation 104:2660-5. 2001
    ..008), or vascular occlusion (P=0.005) when compared with the moderate strategy. CONCLUSIONS: A strategy of aggressive lipid lowering results in significantly less atherosclerosis progression than a moderate approach in LMCAs...
  8. ncbi A summary of the findings from the Post-CABG trial
    B J Hoogwerf
    Cleveland Clinic Foundation, University of Minnesota, Cleveland, USA
    Minerva Cardioangiol 50:291-9. 2002
    ..At the time of the extended follow-up the aggressive lipid strategy was associated with reduced clinical events; low dose warfarin was also associated with reduced clinical events...
  9. ncbi Safety of rosuvastatin
    James Shepherd
    Department of Vascular Biochemistry, University of Glasgow, Glasgow, Scotland
    Am J Cardiol 94:882-8. 2004
    ..Rosuvastatin was well tolerated by a broad range of patients who had dyslipidemia, and its safety profile was similar to those of the comparator statins investigated in this extensive clinical program...
  10. ncbi Plasma homocysteine levels in living kidney donors before and after uninephrectomy
    Michael Y Tsai
    Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis, 55455 0392, USA
    J Lab Clin Med 143:340-3. 2004
    ..Our results, the first to be obtained from living kidney donors, support the hypothesis that renal metabolism of tHcy is the mechanism responsible for the correlation between renal function and plasma tHcy level...
  11. ncbi Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial
    Peter H Jones
    Section of Atherosclerosis and Lipid Research, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Ther 26:1388-99. 2004
    ....
  12. ncbi Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. 2003
    James Shepherd
    Atheroscler Suppl 5:115-23. 2004
  13. ncbi Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals
    James Shepherd
    Department of Pathological Biochemistry, Royal Infirmary, University of Glasgow, Scotland, United Kingdom
    Am J Cardiol 91:11C-17C; discussion 17C-19C. 2003
    ..001). A total of 71% of patients treated with rosuvastatin 10 mg who had triglyceride levels > or =200 mg/dL met both their LDL cholesterol and their non-high-density lipoprotein cholesterol goals...
  14. ncbi Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome
    Prakash C Deedwania
    VA Central California Health Care System and University of California-San Francisco, Fresno, California, USA
    Am J Cardiol 95:360-6. 2005
    ..Rosuvastatin had the most favorable effect on the atherogenic lipid profile of MS overall...
  15. ncbi Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study
    Michael J Koren
    Jacksonville Center for Clinical Research, Jacksonville, Florida, USA
    J Am Coll Cardiol 44:1772-9. 2004
    ....
  16. ncbi Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
    Scott M Grundy
    J Am Coll Cardiol 44:720-32. 2004
    ..Finally, for people in lower-risk categories, recent clinical trials do not modify the goals and cutpoints of therapy...
  17. ncbi Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines
    Scott M Grundy
    Arterioscler Thromb Vasc Biol 24:e149-61. 2004
    ..Finally, for people in lower-risk categories, recent clinical trials do not modify the goals and cutpoints of therapy...
  18. ncbi A summary of implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines
    Scott M Grundy
    Arterioscler Thromb Vasc Biol 24:1329-30. 2004
  19. ncbi Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines
    Scott M Grundy
    Circulation 110:227-39. 2004
    ..Finally, for people in lower-risk categories, recent clinical trials do not modify the goals and cutpoints of therapy...
  20. ncbi Effects of lipid-altering treatment in diabetes mellitus and the metabolic syndrome
    Prakash C Deedwania
    formerly with the Heart Disease Prevention Clinic, University of Minnesota, Minneapolis, Minnesota, USA
    Am J Cardiol 93:18C-26C. 2004
    ..Prospective data from clinical trials examining the preventive effects of lipid-altering therapy in MS patients are needed to better define potential benefits and optimal treatment in this population...
  21. ncbi Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS)
    Christie M Ballantyne
    Baylor College of Medicine, Houston, Tex 77030, USA
    Am Heart J 146:862-9. 2003
    ..Previous studies have shown that effects on high-density lipoprotein cholesterol (HDL-C) may differ among statins...
  22. ncbi Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome
    Donald B Hunninghake
    Heart Disease Prevention Clinic, University of Minnesota, Minneapolis, Minnesota, USA
    Clin Ther 25:1670-86. 2003
    ..However, although atorvastatin produced slightly larger decreases in TG, simvastatin produced larger increases in HDL-C...
  23. ncbi Angiographic changes in saphenous vein grafts are predictors of clinical outcomes
    Genell L Knatterud
    Maryland Medical Research Institute, Baltimore, MD 21210, USA
    Am Heart J 145:262-9. 2003
    ..6 mm in lumen diameter at site of greatest change from baseline)...
  24. ncbi Cardiovascular disease in chronic obstructive pulmonary disease
    Donald B Hunninghake
    U S Medical Affairs, Field Medical, AstraZeneca LP, 1800 Concord Pike, Wilmington, DE 19850
    Proc Am Thorac Soc 2:44-9. 2005
    ..Efforts are currently underway to determine if such antiinflammatory effects are independent of or in addition to simply lowering low-density lipoprotein cholesterol...